The US FDA has approved Fujirebio Diagnostics’ Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, a blood test for early detection of Alzheimer’s disease in adults aged 55 and older. The test measures plasma levels of pTau217 and β-amyloid 1-42 proteins. The clearance was based on the results from a clinical test of 499 plasma samples. Fujirebio’s new test sets a benchmark for other blood tests to meet, according to analyst Puneet Souda.
Hillary Clinton shares condolences after Biden's cancer diagnosis
Former US President Joe Biden has been diagnosed with an aggressive form of prostate cancer. Former Secretary of State Hillary Clinton expressed her support, recognizing
